Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10878380 | PMC |
http://dx.doi.org/10.1164/rccm.202312-2248ED | DOI Listing |
Pediatr Pulmonol
January 2025
Department of Clinical Research, Faculty of Health sciences, University of Southern Denmark, Odense, Denmark.
Introduction: A main feature of CDH is lung hypoplasia and the related presentation of pulmonary hypertension and cardiac dysfunction. Multiple factors influence pulmonary status after CDH: degree of hypoplasia, ventilator-induced injury, altered growth and development of pulmonary structures, reduced diaphragm function and chest wall abnormalities. The evolution of pulmonary sequela in this population is still unclear.
View Article and Find Full Text PDFClin Exp Allergy
January 2025
Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK.
Acta Bioeng Biomech
June 2024
1Institute of Applied Sciences, Academy of Physical Education, Kraków, Poland.
: The aim of this study was to investigate the effect of substrate - polycaprolactone (PCL)-based porous membrane modified with rosmarinic acid (RA), (PCL-RA) and to determine the optimal values of low field laser irradiation (LLLT) as stimulators of biological response of RAW 264.7 macrophages. : The porous polymer membrane was obtained by the phase inversion method, the addition of rosmarinic acid was 1%wt.
View Article and Find Full Text PDFEchocardiography
February 2025
Department of Cardiology, MedStar Georgetown University Hospital, Washington, DC, USA.
Objective: This study evaluated the safety and efficacy of isoproterenol administration as an adjunct for achievement of target heart rate (HR) during dobutamine stress echocardiography (DSE).
Background: In DSE, optimal accuracy is achieved when a target HR of 85% of maximal predicted heart rate (MPHR) is attained. Although rarely studied, intravenous isoproterenol has been used as an adjunct therapy to dobutamine and atropine to increase chronotropic response during pharmacologic stress testing.
Background: In patients with asthma, bronchoconstriction and airway inflammation both contribute to airway narrowing and airflow limitations, which lead to symptoms and exacerbations. Short-acting beta 2-agonist (SABA)-only rescue therapy addresses only bronchoconstriction and is associated with increased morbidity and mortality. Current asthma management guidelines recommend concomitant treatment of symptoms and inflammation with a fast-acting bronchodilator and inhaled corticosteroid (ICS) as rescue therapy for patients 12 years of age.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!